Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment

This open label, parallel‐group study investigated the pharmacokinetics and safety of a single oral 2‐mg dose of the novel selective progesterone receptor modulator vilaprisan in participants with impaired renal function compared with age, weight, sex, and race matched controls with normal renal fun...

Descripción completa

Detalles Bibliográficos
Autores principales: Schultze‐Mosgau, Marcus‐Hillert, Lasseter, Kenneth C., Marbury, Thomas, Loewen, Stephanie, Riecke, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
NON COVID RELATED ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496433/
https://www.ncbi.nlm.nih.gov/pubmed/32227643
http://dx.doi.org/10.1002/jcph.1608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496433/
https://www.ncbi.nlm.nih.gov/pubmed/32227643
http://dx.doi.org/10.1002/jcph.1608

Ejemplares similares